Administration officials reversed a decision made during the Biden presidency that would have given millions of people access to weight-loss drugs paid for Medicare and Medicaid.

President Donald Trump's administration has decided not to cover expensive, high-demand obesity treatments under the government-funded Medicare program

The Centers for Medicare & Medicaid Services will not cover drugs when exclusively used for weight loss, like Ozempic or Wegovy, the Trump administration announced.